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Objective To report our experience using neurally adjusted ventilatory assist (NAVA), which allows a patient to
synchronize spontaneous respiratory effort with mechanical ventilation, in the neonatal intensive care unit in neo-
nates weighing <1500 g.
Study design This was a retrospective review performed between May 2008 and May 2009. A total of 52 neo-
nates on conventional ventilation were converted to NAVA. We compared ventilatory parameters and blood gas
values during conventional ventilation and then at various time intervals during NAVA and evaluated for complica-
tions. Statistical analyses were performed using the 2-tailed Student t-test and the Z-test for proportions for demo-
graphic data and Hotelling’s T2 test to compare repeated measures (P < .05).
Results Peak inspiratory pressure and fraction of inspired oxygen decreased, and pH and partial pressure of
carbon dioxide improved during use of NAVA. These changes were sustained for 24 hours.
Conclusion Compared with standard conventional ventilation, in preterm neonates NAVA appears to pro-
vide better blood gas regulation with lower peak inspiratory pressure and oxygen requirements. (J Pediatr
2012;160:786-9).
N
eurally adjusted ventilatory assist (NAVA), a proprietary product that can be used only with the Servo-I ventilator
(MAQUET, Solna, Sweden), is a ventilation mode that allows the user to synchronize spontaneous respiratory effort
with mechanical ventilation. Current ventilators use a change in airway flow as the trigger to initiate a mechanical
breath. This mechanical breath has a set tidal volume or peak inspiratory pressure (PIP) and inspiratory and expiratory
time that may or may not be in synchrony with the patient. False triggering and missed triggering are common problems
with this type of trigger.1,2 Alternatively, NAVA uses the electromyographic signal in the diaphragm and synchronizes the me-
chanical breath with this electrical activity. Electrodes are embedded within a nasogastric catheter and positioned at the level of
the diaphragm using a retrocardiac electrocardiogram signal. These electrodes continuously detect the amplitude, duration,
and frequency of the electrical activity of the diaphragm (Edi) and transmit this information to the ventilator. The ventilator
breath is triggered and terminated by changes in this electrical activity. The ventilator determines the inspiratory pressure in
proportion to this electrical signal. The patient thus determines respiratory rate (RR), tidal volume, PIP, mean airway pressure
(MAP), and inspiratory and expiratory times.3 Table I summarizes properties of NAVA and conventional ventilation.
AlthoughNAVA has Food andDrug Administration approval for use in patients as small as 500 g, there are limited data on the
use of NAVA in neonates,4-7 and no data on the efficacy of NAVA when used for longer than a few hours. Beck et al6 reported
improved patient–ventilator interaction in low birth weight neonates during a 20-minute trial of NAVA. Other reports include
those fromBreatnach et al,5 who observed improved patient–ventilator synchrony during a 4-hour trial, and Bengtsson et al,7 who
evaluated 30-minute study periods in children undergoing congenital heart surgery. Here we report our experience withNAVA in
the neonatal intensive care unit (NICU) in selected neonates weighing <1500 g who met the criteria for tolerating NAVA.CLD Chronic lung disease
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Table I. Comparison of conventional ventilation and
NAVA
Conventional ventilation NAVA
Patient controls using flow trigger Patient controls using neural trigger
Initiation of breath Initiation of breath
Rate (in some modes) Rate
Inspiratory time
Peak pressure
Breath termination
Ventilator controls Ventilator controls
PEEP PEEP
FiO2 FiO2
Peak pressure or tidal volume NAVA level
Inspiratory time
Minimum rate
Breath termination (expiratory time)
Synchrony Synchrony
Initiation of breath Initiation of breath
Double, false, and missed triggering Size of breath
Termination of breath
PEEP, positive end-expiratory pressure.
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year that NAVA was used in the NICU, so the decision to
use NAVA was based on the attending physician’s comfort
level with NAVA, not on the patient’s clinical status. This
allowed us to then retrospectively compare PIP, MAP, RR,
and fraction of inspired oxygen (FiO2) at 1, 4, 12, and 24
hours and pH and pCO2 at 1 and 24 hours during SIMV-
PC and after conversion to NAVA. We considered neo-
nates placed on NAVA between 0 and 10 days of age to
have respiratory distress syndrome (RDS). For the purpose
of this analysis, we defined neonates still ventilator-
dependent after 15 days of age as having chronic lung dis-
ease (CLD). In addition, we also evaluated the occurrence
of grade 3 or 4 intraventricular hemorrhage, pneumothor-
acies, and necrotizing enterocolitis or spontaneous perfo-
ration in infants receiving NAVA.
Statistical analyses were performed using the 2-tailed
Student t-test and Z-test for proportions for the demographic
data and Hotelling’s T2 test to compare repeated measure
with the ventilatory parameters. A P value <.05 was consid-
ered significant.
Results
A total of 52 neonates weighing <1500 g were ventilated with
NAVA between May 2008 and May 2009. Thirty-one neo-
nates were placed on NAVA between 0 and 10 days of age
and were considered to have RDS for the purpose of this anal-
ysis; 21 neonates were placed on NAVA after 15 days of age
and were considered to have CLD. Eleven neonates (7 with
RDs and 4 with CLD) received NAVA for less than 12 hours
due to recurrent apnea. These neonates were included in each
respective analysis and also evaluated as a separate group.
Table II (available at www.jpeds.com) presents the
maternal and neonatal variables of the entire study group
and in the neonates with RDS, those with CLD, and thosewho failed NAVA. Table III presents demographic data for
the study group and in the neonates with RDS, those with
CLD, and those who failed NAVA. The neonates with RDS
were older at birth and weighed more than those with CLD
and those who failed NAVA. There was no difference in
weight between the neonates with RDS and those with
CLD when started on NAVA, but, as expected, the
neonates with CLD were older.
For all neonates, SIMV-PC was provided using stan-
dardized settings, including a positive end-expiratory pres-
sure of 5 cm H2O and inspiratory time of 0.33 seconds.
A neonate had to be breathing above the set ventilator
rate to be eligible for the trial of NAVA. The NAVA num-
ber is a conversion factor that converts the Edi signal into
a proportional pressure. The higher the NAVA number,
the more work the ventilator does (functioning as an ac-
cessory diaphragm); the lower the NAVA number, the
more work the patient does. Each patient adjusts his or
her own Edi, using breath-to-breath feedback, to deliver
the desired pressure, so that the actual NAVA number
makes no difference to the ventilator pressure delivered.
The initial NAVA number was chosen in accordance
with the manufacturer’s guidelines and, after an initial
adjustment period, was not changed during the first 24
hours. The NAVA number ranged between 1 and 2.5 cm
H2O/mV, and a positive end-expiratory pressure of 5 cm
H2O was maintained. Backup settings were chosen to
match the pre-NAVA ventilator settings.
Ventilatory parameters for all neonates are presented in
Table IV. The neonates demonstrated decreases in PIP and
FiO2 at 1 hour after conversion from SIMV-PC to NAVA.
These changes were sustained at 4, 12, and 24 hours. There
was no change in MAP or RR after the change from SIMV-
PC to NAVA.
Blood gas values during SIMV-PC and then during
NAVA were not available in 3 of the 52 neonates, who
did not receive NAVA long enough to undergo 1-hour
blood gas analysis. In the remaining 49 neonates, blood
gas analysis was done in the entire cohort and then in those
with pH #7.35 or pCO2 $45 (33 neonates). These neonates
showed a significant improvement in pH at 1 and at 24
hours after the switch from SIMV-PC to NAVA. These
neonates also had significantly decreased pCO2 after
1 hour and 24 hours of NAVA. The 16 neonates with
pH $7.35 or pCO2 <45 showed no significant change in
blood gas values while receiving NAVA (Table IV).
Table V presents the ventilatory parameters and blood
gas values in neonates with RDS, those with CLD, and
those who failed NAVA when changing from SIMV-PC
to NAVA. Decreased PIP and FiO2 and improved pH
and pCO2 were evident in the neonates with RDS or
CLD. Although the neonates who failed NAVA had
excessive apnea, they did not demonstrate respiratory
deterioration. Their PIP, FiO2, and blood gas values
remained stable during NAVA compared with SIMV-PC.
RR and MAP also did not change after the switch from
SIMV-PC to NAVA. None of these neonates had any787
Table III. Demographic data for the entire cohort and neonates with RDS, neonates with CLD, and neonates who failed
NAVA
All (n = 52) RDS (n = 31) CLD (n = 21) Failed trial (n = 11)
Gestational age, weeks, mean SD (range) 26.3  2.6 27.2  2.6 25  1.8* 24.6  1.8*
Range 22-32 23-32 22-28 22-28
Birth weight, g, mean SD (range) 837  271 930  285 702  184* 714  234*
Range 440-1493 550-1493 440-1010 440-1260
Age at study, days, mean SD (range) 15  15 4  3 31  11* 14  13*†
Range 0-56 0-10 15-56 0-45
Weight at study, g, mean SD (range) 958  294 927  275 1001  309 776  277†
Range 465-1870 530-1490 465-1870 465-1270
Of the 11 neonates who failed NAVA, 7 had RDS and 4 had CLD. Their data are also included in each category as well as presented separately.
*P < .05 compared with RDS.
†P < .05 compared with CLD.
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necrotizing enterocolitis or spontaneous perforation while
receiving NAVA.
Discussion
Here we report a series of neonates weighing <1500 g who
were successfully ventilated with NAVA in the NICU for
up to 24 hours. Beck et al6 previously reported improved
patient–ventilator interaction in low birth weight neonates
during a brief 20-minute trial of NAVA. Additional re-
ports include those from Breatnach et al,5 who observed
improved patient–ventilator synchrony on a 4-hour trial
of NAVA in children aged 2 days to 4 years, and Bengtsson
et al,7 who evaluated 30-minute periods of NAVA use in
21 children undergoing congenital heart surgery (but
only 4 children aged <1 month and no preterm neonates).
The present study found that PIP and FiO2 decreased sig-
nificantly just 1 hour after the switch to NAVA, and that
these improvements were sustained over 12-24 hours.
Our findings are consistent with other, shorter studies
that reported a similar reduction in peak airway pressure
in term infants ventilated with NAVA,5,7 but demonstrate
that these improvement also occur in extremely preterm
neonates and are sustained over 24 hours. We believe
that NAVA’s ability to allow for lower PIP and lower
FiO2 settings in the face of improved blood gas values
compared with standard conventional ventilation supportsTable IV. Ventilatory parameters and blood gases on SIMV-
SIMV-PC NAVA 1 hour
PIP, cm H2O 17.4  3 13.6  4.1
FiO2 0.32  0.12 0.27  0.07
RR, bpm 53  12 55  17
MAP, cm H2O 8.7  1.5 7.6  1.9
pH (all) 7.34  0.08 7.35  0.05
pH #7.35 7.29  0.05 7.32  0.04
pH >7.35 7.42  0.04 7.39  0.03
pCO2 (all), Torr 47  10 46  7
pCO2 $45 54  7 50  6
pCO <45 38  5 41  6
*P < .05 difference from SIMV-PC by Hotelling’s T 2 test for repeated measures.
788its potential efficacy as ventilatory therapy to minimize
both permissive hypercapnia and lung injury in low birth
weight preterm infants.8,9 Ventilating with NAVA allows
the neonate to determine its own pCO2 and pH based
on continuous feedback from its mechanoreceptors and
chemoreceptors. These feedback loops appear to be intact
in premature neonates, as our results demonstrate. Achiev-
ing similar blood gas results with SIMV-PC would require
manually increasing minute ventilation by increasing ei-
ther tidal volume or RR. During NAVA, spontaneous RR
was unchanged, so improvements in minute ventilation
likely were the result of increases in tidal volume, support-
ing the concept that NAVA allows neonates to improve
their tidal volumes and decrease PIP. The most likely rea-
son for this result is improved patient–ventilator syn-
chrony. Sinderby3 described this concept of how patient–
ventilator synchrony achieved with NAVA decreases the
work of breathing, protects the lung from injury by avoid-
ing excessive volume delivery, and facilitates the participa-
tion of respiratory muscles in breathing. In addition to
limiting ventilator-induced lung injury, based on these
principles, NAVA also may have the potential to promote
weaning and facilitate earlier extubation. Of note, al-
though PIP was lower during NAVA with a similar RR,
MAP was not different compared with SIMV-PC. This
may be secondary to the changes in inspiratory and expi-
ratory times that have been reported in neonates receiving
conventional ventilation and those receiving NAVA.6,10PC and on NAVA in neonates weighing <1500 g
NAVA 4 hours NAVA 12 hours NAVA 24 hours
13.4  3.8 13.3  4.1 12.6  3.6*
0.25  0.07 0.26  0.07 0.28  0.07*
56  16 55  14 59  15
8.1  2.1 8.3  2.1 8  1.5
7.36  0.05
7.34  0.5*
7.4  0.5
45  6
47  4*
41  5
Stein and Howard
Table V. Ventilatory parameters and blood gases on SIMV-PC and NAVA in neonates with RDS, those with CLD, and
those who failed NAVA
SIMV-PC NAVA 1 hour NAVA 4 hours NAVA 12 hours NAVA 24 hours
RDS (n = 31)
PIP (cm H2O) 16.5  2 12.1  3.5 12.7  3.8 13.2  4.1 11.3  2.9*
FiO2 0.28  0.06 0.25  0.06 0.23  0.04 0.24  0.05 0.24  0.07*
pH #7.35 7.29  0.06 7.32  0.03 7.33  0.03*
pCO2 $45 55  9 48  5 45  6*
CLD (n = 21)
PIP (cm H2O) 18.5  3.6 15.9  3.9 14.3  3.8 13.4  4.2 13.4  3.8*
FiO2 0.37  0.15 0.3  0.09 0.3  0.7 0.28  0.07 0.27  0.06*
pH #7.35 7.31  0.02 7.33  0.02 7.37  0.05*
pCO2 $45 53  4 50  4 48  5*
Failed (n = 11)
PIP (cm H2O) 17.8  3.5 13.9  5.1 13.1  6.4
FiO2 0.32  0.13 0.28  0.06 0.26  0.07
pH #7.35 7.31  0.04 7.31  0.08
pCO2 $45 50  3 46  3
Of the 11 who failed NAVA, 7 had RDS and 4 had CLD. Their data are also included in each category as well as separately.
*P < .05 difference from SIMV-PC by Hotelling’s T 2 test for repeated measures.
May 2012 ORIGINAL ARTICLESThe neonates who failed NAVA demonstrated no deteri-
oration in ventilatory parameters but were taken off NAVA
because of frequent apnea. Apnea of prematurity is typical
in this population. To account for this, the apnea time
can be preset so that the ventilator will provide backup
(ie, pressure control) ventilation if the neonate demon-
strates no respiratory effort for this predetermined time.
During the first year after the introduction of NAVA, the
software was limited by an inability to cycle back and forth
between NAVA and backup ventilation. Each time the neo-
nate experienced apnea, the ventilator alarm would sound,
signaling the need to manually reset to NAVA. This need to
have someone at the bedside limits the use of NAVA in ne-
onates with frequent apnea. A neonate experiencing multi-
ple apneic episodes was taken off NAVA because of
operator fatigue and was considered a NAVA ‘‘failure.’’ In
reality, it was the software that failed the neonate. Today,
with the new software updates, a neonate can switch spon-
taneously back and forth between NAVA and backup as
needed, and frequent apnea is no longer a contraindication
to the use of NAVA.
Limitations of this study include its retrospective nature,
meaning that such data as severity of apneic events and Edi
values were not available. In addition, the definitions of
RDS and CLD for our study cohort do not conform to the
commonly used definitions. Future studies will include these
parameters.
Our study population developed no short-term complica-
tions related to the switch from SIMV-PC to NAVA. Of note,
no neonate experienced pneumothoracies, intraventricular
hemorrhage, or necrotizing enterocolitis or spontaneous per-
foration while receiving NAVA. Further studies including
larger prospective trials of the use of NAVA in preterm neo-
nates are needed to better evaluate its safety and its effect on
long-term outcome. These findings support the future utility
of studying NAVA in preterm neonates as an alternativeNeurally Adjusted Ventilatory Assist in Neonates Weighing <1500method of ventilation with the potential to create less acute
and chronic lung injury. n
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Table II. Maternal and neonatal variables (as %) in
neonates weighing <1500 g ventilated with NAVA
All
(n = 52)
RDS
(n = 31)
CLD
(n = 21)
Failed trial
(n = 11)
Maternal variables
Maternal diagnosis
Preterm labor 61 59 66 82
Pregnancy-induced
hypertension
25 35 10* 0*
Abruption 14 6 24* 18
Prenatal steroid use 69 77 57 64
Spontaneous vaginal
delivery
31 26 38 27
Neonatal variables
Apgar score
1 minute
0-3 29 29 29 36
4-6 40 42 38 27
5 minute
0-3 11 10 14 27
4-6 17 13 24 18
Surfactant
Any 100 100 100 100
3-4 doses 64 58 71 73
Caffeine before NAVA 88 79 100* 100
Steroids before NAVA 4 0 5 50*†
*P < .05 compared to RDS.
†P < .05 compared to RDS and CLD.
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